Search results for " Progressive"

showing 10 items of 105 documents

NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study

2021

Background: Easily accessible biomarkers enabling the identification of those patients with multiple sclerosis (MS) who will accumulate irreversible disability in the long term are essential to guide early therapeutic decisions. We here examine the utility of serum neurofilament light chain (sNfL) for forecasting relapse-free disability progression and conversion to secondary progressive MS (SPMS) in the prospective Neurofilament and longterm outcome in MS (NaloMS) cohort. Methods: The predictive ability of sNfL at Baseline and sNfL follow-up (FU)/ Baseline (BL) ratio with regard to disability progression was assessed within a development cohort (NaloMS, n=196 patients with relapsing-remitt…

AdultMaleOncologymedicine.medical_specialtyMedicine (General)Logistic regressionGeneral Biochemistry Genetics and Molecular BiologyMultiple sclerosisYoung AdultMultiple Sclerosis Relapsing-RemittingR5-920Neurofilament ProteinsInterquartile rangeInternal medicinemedicineHumansLongitudinal StudiesProspective StudiesRisk factorNeurofilament light chainSPMS transitionDisease progressionClinically isolated syndromebusiness.industryRGeneral MedicineOdds ratioMultiple Sclerosis Chronic ProgressiveConfidence intervalCohortMedicineFemalebusinessBiomarkersResearch PaperCohort studyEBioMedicine
researchProduct

Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective ana…

2014

Abstract Background Mitoxantrone is used on an off-label basis in primary progressive MS (PPMS). ABC -transporter-genotypes are associated with therapeutic response in relapsing/secondary progressive MS (RP/SPMS). Objective To evaluate potential pharmacogenetic response markers for mitoxantrone in PPMS. Methods 41 mitoxantrone-treated PPMS-patients, 155 mitoxantrone-treated RP/SPMS-patients and 43 PPMS-controls were retrospectively assessed for clinical therapy-response and in correlation with four single-nucleotide-polymorphisms in ABCB1 - and ABCG2 -genes. Results 53.7% PPMS-patients were mitoxantrone-responders, in comparison to 78.1% of RP/SPMS-patients (p = 0.039). There was no associa…

AdultMaleOncologymedicine.medical_specialtyTreatment responseATP Binding Cassette Transporter Subfamily Bmedicine.medical_treatmentImmunologyPrimary Progressive Multiple SclerosisPharmacologyInternal medicineGenotypeLack of efficacymedicineRetrospective analysisATP Binding Cassette Transporter Subfamily G Member 2HumansImmunology and AllergyRetrospective StudiesAnalgesicsMitoxantronebusiness.industryImmunosuppressionMiddle AgedMultiple Sclerosis Chronic ProgressiveNeoplasm Proteins3. Good healthNeurologyPharmacogeneticsATP-Binding Cassette TransportersFemaleNeurology (clinical)MitoxantronebusinessPharmacogeneticsmedicine.drugJournal of Neuroimmunology
researchProduct

Impairments in proverb interpretation following focal frontal lobe lesions.

2012

The proverb interpretation task (PIT) is often used in clinical settings to evaluate frontal “executive” dysfunction. However, only a relatively small number of studies have investigated the relationship between frontal lobe lesions and performance on the PIT. We compared 52 patients with unselected focal frontal lobe lesions with 52 closely matched healthy controls on a proverb interpretation task. Participants also completed a battery of neuropsychological tests, including a fluid intelligence task (Raven’s Advanced Progressive Matrices). Lesions were firstly analysed according to a standard left/right sub-division. Secondly, a finer-grained analysis compared the performance of patients w…

AdultMalePFCCognitive NeuroscienceExperimental and Cognitive PsychologyNeuropsychological TestsFluid intelligencebehavioral disciplines and activities050105 experimental psychologyFunctional LateralityArticle03 medical and health sciencesBehavioral Neuroscience0302 clinical medicineRaven's Progressive MatricesExecutive functionmedicineHumans0501 psychology and cognitive sciencesIn patientPrefrontal cortexStrokeAgedSettore M-PSI/02 - Psicobiologia E Psicologia Fisiologica05 social sciencesNeuropsychologyAnatomyMiddle Agedmedicine.diseasefrontal lobeStrokeFrontal lobeSchizophreniaBrain InjuriesMetaphorFemaleFluid intelligencePsychologyComprehensionNeuroscienceProverbs030217 neurology & neurosurgery
researchProduct

Sensory processing in children with Autism Spectrum Disorder: Relationship with non-verbal IQ, autism severity and Attention Deficit/Hyperactivity Di…

2015

Abstract The main objective of this study was to analyze in a sample of children with ASD the relationship between sensory processing, social participation and praxis impairments and some of the child's characteristics, such as non-verbal IQ, severity of ASD symptoms and the number of ADHD symptoms (inattention and hyperactivity/impulsivity), both in the home and main-classroom environments. Participants were the parents and teachers of 41 children with ASD from 5 to 8 years old ( M  = 6.09). They completed the Sensory Processing Measure (SPM) to evaluate sensory processing, social participation and praxis; the Gilliam Autism Rating Scale (GARS-2) to evaluate autism severity; and a set of i…

AdultMaleParentsSensory processingAutism Spectrum Disordermedicine.medical_treatmentContext (language use)EnvironmentImpulsivitySeverity of Illness Indexbehavioral disciplines and activitiesDevelopmental psychologyPerceptual DisordersCognitionRaven's Progressive MatricesRating scaleSurveys and Questionnairesmental disordersDevelopmental and Educational PsychologymedicineHumansAttention deficit hyperactivity disorderChildIntelligence TestsfungiMiddle AgedSocial Participationmedicine.diseaseFacultyClinical PsychologyAttention Deficit Disorder with HyperactivityAutism spectrum disorderChild PreschoolAutismFemalePerceptionmedicine.symptomPsychologyResearch in Developmental Disabilities
researchProduct

Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study

2009

Background To investigate in a large cohort of patients with multiple sclerosis (MS), lesion load and atrophy evolution, and the relationship between clinical and magnetic resonance imaging (MRI) correlates of disease progression. Methods Two hundred and sixty-seven patients with MS were studied at baseline and two years later using the same MRI protocol. Abnormal white matter fraction, normal appearing white matter fraction, global white matter fraction, gray matter fraction and whole brain fraction, T2-hyperintense, and T1-hypointense lesions were measured at both time points. Results The majority of patients were clinically stable, whereas MRI-derived brain tissue fractions were signifi…

AdultMalePathologymedicine.medical_specialtyAdolescentCentral nervous systemmultiple sclerosisSeverity of Illness IndexLesion loadWhite matterCentral nervous system diseaseYoung AdultDegenerative diseaseAtrophyMultiple Sclerosis Relapsing-RemittingatrophyRisk FactorsT2 lesionsmedicinefollow upHumansAgedmedicine.diagnostic_testbusiness.industryMultiple sclerosisBrain AtrophyBrainMagnetic resonance imagingMiddle AgedMultiple Sclerosis Chronic Progressivelesion loadmedicine.diseaseMagnetic Resonance Imagingmedicine.anatomical_structureCross-Sectional StudiesLogistic ModelsNeurologymultiple sclerosiMultivariate AnalysisDisease ProgressionFemaleSettore MED/26 - NeurologiaNeurology (clinical)businessFollow-Up StudiesMRI
researchProduct

Proteinase-3 mRNA expressed by glomerular epithelial cells correlates with crescent formation in Wegener's granulomatosis

2000

Proteinase-3 mRNA expressed by glomerular epithelial cells correlates with crescent formation in Wegener's granulomatosis. Background Wegener's granulomatosis (WG) is characterized by systemic vasculitis with crescentic glomerulonephritis (CGN) and circulating autoantibodies directed against neutrophil cytoplasmic antigens (ANCA). Proteinase 3 (PR-3), a neutral serine proteinase in neutrophils implicated in the growth control of myeloid cells, has been identified as the target antigen for ANCA in WG. Since the kidneys are frequently involved in WG, we studied the in situ expression of PR-3 by renal parenchymal cells. Methods We assessed the expression of PR-3 in kidney biopsies of 15 patien…

AdultMalePathologymedicine.medical_specialtyBiopsyMyeloblastinKidney GlomerulusIn situ hybridizationBiologyurologic and male genital diseasesKidneyvasculitisAntigenProteinase 3medicineRapidly progressive glomerulonephritisHumanscrescent glomerulonephritisNorthern blotRNA Messengerrapidly progressive glomerulonephritisCells CulturedAgedKidneyANCAurogenital systemSerine EndopeptidasesGranulomatosis with PolyangiitisEpithelial CellsMiddle Agedmedicine.diseasekidney parenchymal cellsmedicine.anatomical_structureKidney TubulesNephrologyImmunohistochemistryFemaleSystemic vasculitisKidney International
researchProduct

No Association Between Genetic Polymorphism at Codon 129 of the Prion Protein Gene and Primary Progressive Multiple Sclerosis

2011

AdultMalePrionsChromosomes Human Pair 20Primary Progressive Multiple SclerosisPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineArts and Humanities (miscellaneous)HumansMedicineGenetic Predisposition to DiseasePrion proteinCodonGene030304 developmental biologyGenetics0303 health sciencesbusiness.industryMiddle AgedMultiple Sclerosis Chronic ProgressivePrnp geneFemaleNeurology (clinical)business030217 neurology & neurosurgeryArchives of Neurology
researchProduct

Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study

2007

In patients with relapsing-remitting multiple sclerosis (MS), IVIG was shown to reduce the relapse rate and progression of disability. In patients with chronic progressive MS, a beneficial effect of IVIG was not documented in placebo controlled studies. This trial investigated the influence of IVIG in primary (PPMS) and secondary (SPMS) chronic progressive MS. Two-hundred and thirty-one patients stratified for PPMS ( n = 34) and SPMS ( n = 197) were randomly assigned to IVIG 0.4 g/kg per month or to placebo for 24 months. Primary endpoints were 1) the time to sustained progression of disease identified as worsening of the expanded disability status scale (EDSS) sustained for 3 months, and …

AdultMalemedicine.medical_specialtyDiseasePlaceboPlacebosCentral nervous system diseaseDisability EvaluationDegenerative diseaseQuality of lifeRecurrencehemic and lymphatic diseasesInternal medicinemedicineHumansImmunologic FactorsProspective StudiesDepression (differential diagnoses)AgedExpanded Disability Status Scalebusiness.industryMultiple sclerosisImmunoglobulins IntravenousMiddle AgedMultiple Sclerosis Chronic Progressivemedicine.diseaseSurgeryTreatment OutcomeNeurologyDisease ProgressionFemaleNeurology (clinical)businessMultiple Sclerosis Journal
researchProduct

Early imaging predicts later cognitive impairment in primary progressive multiple sclerosis

2010

Background: Cognitive impairment in primary progressive multiple sclerosis (PPMS) is common and correlates modestly with contemporary lesion burden and brain volume. Using a cohort/case control methodology, we explore the ability of MRI abnormalities, including those in the normal-appearing brain tissue, to predict future cognitive dysfunction in PPMS. Methods: Thirty-one patients recruited into a longitudinal study within 5 years of onset of PPMS were assessed neuropsychologically on average 5.5 years later along with 31 matched healthy controls. MRI data obtained at entry into the study (lesion metrics, brain volumes, magnetization transfer ratio histogram metrics, and magnetic resonance …

AdultMalemedicine.medical_specialtyMagnetic Resonance SpectroscopyTime Factorsprimary progressive multiple sclerosisNeuropsychological TestsAudiologyNerve Fibers MyelinatedLesionWhite matterCentral nervous system diseasemedicineHumansLongitudinal StudiesAgedNerve Fibers UnmyelinatedMultiple sclerosisCognitive disorderBrainCognitionOrgan SizeMiddle AgedMultiple Sclerosis Chronic Progressivemedicine.diseaseMagnetic Resonance Imagingmedicine.anatomical_structureCase-Control StudiesBrain sizeFemaleNeurology (clinical)Verbal memorymedicine.symptomCognition DisordersPsychologyNeuroscienceFollow-Up StudiesNeurology
researchProduct

Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study.

2014

Objective: The objective of this paper is to identify clinical or magnetic resonance imaging (MRI) predictors of long-term clinical progression in a large cohort of multiple sclerosis (MS) patients. Methods: A total of 241 relapsing–remitting (RR) MS patients were included in a nine-year follow-up (FU) study. The reference MRIs were acquired at baseline (BL) as part of a multicenter, cross-sectional, clinical-MRI study. Volumetric MRI metrics were measured by a fully automated, operator-independent, multi-parametric segmentation method. Clinical progression was evaluated as defined by: conversion from RR to secondary progressive (SP) disease course; progression of Expanded Disability Status…

AdultMalemedicine.medical_specialtyMagnetic resonance imaging follow-up multiple sclerosis clinical predictors gray matter atrophypredictormultiple sclerosisDisease courseDisability EvaluationMultiple Sclerosis Relapsing-RemittingInternal medicinefollow-upmedicineHumansSecondary progressiveExpanded Disability Status Scalemedicine.diagnostic_testbusiness.industryMultiple sclerosisDisease progressionFollow up studiesMagnetic resonance imagingclinical predictorsMiddle Agedmedicine.diseaseMagnetic Resonance Imaginggray matter atrophyCross-Sectional StudiesNeurologymultiple sclerosiDisease ProgressionSettore MED/26 - NeurologiaFemaleNeurology (clinical)businessNuclear medicineClinical progressionMRIFollow-Up StudiesMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct